Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma

Wei Mu, Meilan Zhang, Guang Hu, Yunfeng Han, Xia Mao, Caixia Chen, Ke Shen, Zhenyu Dai, Xiaojian Zhu, Xiaoxi Zhou, Liang Huang, Qilin Ao, Min XiaoFrontiers in Immunology 2023 · DOI

Abstract

This case report (NCT04767308) details the successful treatment of a 17-year-old patient with refractory ALK+ anaplastic large cell lymphoma (ALCL) using novel anti-CD5 CAR-T cell therapy. A critical diagnostic challenge emerged three months post-infusion: a massive expansion of therapeutic CAR-T cells in the lymph nodes clinically and histologically mimicked a cancer relapse. By employing advanced molecular profiling, including T-cell receptor (TCR) repertoire analysis and next-generation sequencing (NGS), clinicians were able to distinguish the "living drug" from malignant cells, confirming a state of complete remission.

Introduction

Treating T-cell lymphomas, such as ALK+ ALCL, remains a significant clinical challenge once they become refractory to standard chemotherapy. While Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment landscape for B-cell malignancies, its application in T-cell cancers faces unique hurdles. A primary concern is "fratricide," where CAR-T cells target and kill each other because the targeted markers (like CD5) are expressed on both the malignant cells and the therapeutic T cells.

Furthermore, this case highlights a high-stakes diagnostic dilemma: distinguishing between disease relapse and robust CAR-T cell expansion. When lymph nodes swell following infusion, standard pathology can be misleading, as activated CAR-T cells often appear "atypical" or "malignant" under a microscope, potentially leading to false-positive diagnoses and unnecessary salvage therapy.

Methods

A multi-omic diagnostic strategy was employed to monitor the patient and differentiate therapeutic cells from malignant ones:

  • Anti-CD5 CAR-T Engineering: Autologous T cells were modified to target CD5. The construct included a truncated EGFR (EGFRt) as a "safety switch" for targeted elimination via cetuximab if required.
  • Molecular Monitoring: Droplet digital PCR (ddPCR) quantified CAR-T transgene copy numbers in peripheral blood. Flow cytometry monitored the loss of CD5 expression and the depletion of target cells.
  • Genomic Profiling: Next-generation sequencing (NGS) screened a panel of 157 lymphoma-related genes for persistent or new oncogenic mutations.
  • TCR Repertoire Analysis: This served as the diagnostic "gold standard." By analyzing TCR rearrangements, the team determined if the lymph node expansion was monoclonal (indicative of cancer) or polyclonal (indicative of a therapeutic CAR-T response).

Results

The patient achieved Complete Remission (CR) and has maintained disease-free survival for over 815 days (as of August 2023).

CAR-T Kinetics and Biochemical Response

CAR-T cells peaked in the peripheral blood at day 14, representing 56.17% of total lymphocytes. This expansion correlated with significant biochemical changes, including a 13-fold increase in IL-6 and a 70-fold increase in ferritin, consistent with Grade 1 Cytokine Release Syndrome (CRS).

TNF-α levels post-infusion showing a peak correlating with CAR-T expansion and Grade 1 CRS.

As shown in the figure above, TNF-α levels also exhibited a sharp peak around day 14, mirroring the CAR-T expansion kinetics and supporting the clinical observation of CRS.

The "Relapse" Mirage

Three months post-infusion, the patient presented with enlarged lymph nodes. Histopathology revealed atypical large cells and a loss of normal lymph node architecture—features typically diagnostic of lymphoma relapse. However, molecular verification proved otherwise. The T cells in the biopsy were CD5-negative and contained the CAR sequence. Crucially, TCR repertoire analysis showed no evidence of a dominant malignant clone, confirming that the "atypical" cells were actually the expanded CAR-T population.

Discussion and Limitations

This study confirms that therapeutic CAR-T cells can undergo significant morphological changes in vivo, adopting a "hyperplastic" appearance that mimics malignancy. This "relapse mirage" underscores the necessity of molecular verification (NGS and TCR analysis) over traditional histopathology in the context of T-cell directed CAR therapies.

Despite the targeting of CD5, the CAR-T cells successfully expanded and persisted without debilitating fratricide. However, the study is limited by its single-patient scope (N=1). While the results are promising, the safety and efficacy of anti-CD5 CAR-T cells require validation in larger cohorts. Additionally, the patient experienced a Grade 4 rash, highlighting that off-tumor toxicities remain a concern. Future research will focus on refining safety switches and determining if CAR-T expansion mimicking relapse is a common phenomenon in T-cell therapies.

Summary updated

Abstract

NCT04767308.
BibTeX
@inproceedings{mu2023case,
  author = {Wei Mu and Meilan Zhang and Guang Hu and Yunfeng Han and Xia Mao and Caixia Chen and Ke Shen and Zhenyu Dai and Xiaojian Zhu and Xiaoxi Zhou and Liang Huang and Qilin Ao and Min Xiao},
  title = {{Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1280007},
}
Figure